Sellas Life Sciences has been downgraded to a Strong Sell rating due to a significant disconnect between its market valuation and the realistic potential of its GPS therapy for acute myeloid leukemia (AML). The company's market cap is nearing $1.5 billion, while the risk-adjusted net present value (NPV) for GPS in AML CR2 is estimated at only $259 million to $550 million under optimistic scenarios. Concerns have arisen following delays in the REGAL Phase 3 trial, which are believed to stem from improvements in the control arm rather than any demonstrated efficacy of GPS. This situation raises the risk of disappointment for investors. Given that much of Sellas's value is tied to the REGAL trial, a negative outcome could result in a stock price drop of over 70%. Additionally, while the company has pipeline assets and cash reserves, these provide limited downside support in the event of adverse trial results. Investors are advised to conduct thorough research and consider the inherent risks associated with stock investments.